Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.30 |
| ▸ | HTR2C | P28335 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13714703 | 0.68 | KDM4E (0.34) | — | |
| SCHEMBL29657636 | 0.67 | CYP1A1 (0.40) | HTR2AHTR2CHTR2B | |
| SCHEMBL6714839 | 0.64 | HTR2A (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL4429415 | 0.61 | PAX8 (0.48) | HTR2AHTR2CHTR2B | |
| SCHEMBL18527205 | 0.60 | HTR2A (0.36) | HTR2AHTR2CHTR2B | |
| SCHEMBL3633037 | 0.59 | HTR2A (0.46) | HTR2AHTR2CHTR2B | |
| SCHEMBL29474440 | 0.59 | HTR2A (0.42) | HTR2AHTR2CHTR2B | |
| SCHEMBL17426271 | 0.57 | PAX8 (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL12278144 | 0.57 | PAX8 (0.45) | HTR2AHTR2CHTR2B | |
| SCHEMBL13714699 | 0.57 | HTR2A (0.31) | HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7576124-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576124-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576123-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-7576123-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2009-08-18 | — | — | US | disclosed |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-02-14 | — | — | US | disclosed |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2008-02-14 | — | — | US | disclosed |
| US-20070244188-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244188-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | BIOAVAILABILITY SYSTEMS, LLC (US) | 2007-10-18 | — | — | US | disclosed |
| US-7230027-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2007-06-12 | — | — | US | disclosed |
| US-7230027-B2 | Anti-first-pass effect compounds | BIOAVAILABILITY SYSTEMS, L.L.C. (US) | 2007-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244188-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | FABP2, ABCG2, NPSR1 | HTR2A 21/4885HTR2C 80/4885HTR2B 43/4885 |
| US-20080039520-A1 | ANTI-FIRST-PASS EFFECT COMPOUNDS | ABCG2, FABP2, HDLBP | HTR2A 171/4885HTR2C 346/4885HTR2B 152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.